Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer

Johnson & Johnson's TAR-200 plus cetrelimab combination therapy shows promising results in reducing tumor size for patients with muscle-invasive bladder cancer, potentially improving surgical outcomes and lowering recurrence risk.